CTKB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
48.1M
+9.1%
44.1M
-29.0%
62.1M
+18.8%
52.3M
+14.7%
45.6M
Cost of Revenue
19.8M
-13.5%
22.9M
-21.8%
29.3M
+18.2%
24.7M
+13.8%
21.7M
Gross Profit
28.3M
+33.3%
21.3M
-35.4%
32.9M
+19.4%
27.6M
+15.4%
23.9M
Operating Expenses
39.7M
+0.1%
39.7M
+3.2%
38.5M
+4.7%
36.7M
+6.5%
34.5M
R&D
9.7M
+1.4%
9.6M
+7.2%
9.0M
+0.1%
9.0M
+1.5%
8.8M
SG&A
30.0M
-0.4%
30.1M
+2.0%
29.5M
+6.2%
27.8M
+8.3%
25.7M
Operating Income
-11400000
+38.3%
-18463000
-230.1%
-5594000
+39.1%
-9192000
+13.5%
-10624000
EBITDA
-9391000
+43.4%
-16598000
-348.8%
-3698000
+49.2%
-7274000
+16.7%
-8734000
Net Income
-12158000
+35.6%
-18866000
+57.2%
-44076000
-704.6%
-5478000
+1.9%
-5583000
EPS (Basic)
$-0.09
+40.0%
$-0.15
+55.9%
$-0.34
-750.0%
$-0.04
+0.0%
$-0.04
EPS (Diluted)
$-0.09
+40.0%
$-0.15
+55.9%
$-0.34
-750.0%
$-0.04
+0.0%
$-0.04
Shares (Diluted)
129.5M
+0.6%
128.7M
+0.4%
128.2M
+0.5%
127.5M
+0.5%
126.9M
Cytek Biosciences (CTKB) โ€” Financials